Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 6/20 | 0.59 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.56 |
| ▸ | MMP2 | P08253 | 3/20 | 0.52 |
| ▸ | MMP9 | P14780 | 3/20 | 0.52 |
| ▸ | MMP8 | P22894 | 3/20 | 0.52 |
| ▸ | MMP13 | P45452 | 3/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | APLNR | P35414 | 1/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2109904 | 0.84 | TAS2R14 (0.68) | TAS2R14APLNRPTGESTAS2R8CXCR3 | |
| SCHEMBL15208353 | 0.83 | BMP1 (0.59) | BMP1TAS2R14MMP2MMP9MMP8 | |
| SCHEMBL9390270 | 0.77 | PKM (0.70) | APLNR | |
| SCHEMBL6322381 | 0.77 | TAS2R14 (0.64) | BMP1TAS2R14MMP2MMP9MMP8 | |
| SCHEMBL6325058 | 0.77 | TAS2R14 (0.61) | BMP1TAS2R14MMP2MMP9MMP8 | |
| SCHEMBL29956254 | 0.76 | TAS2R14 (0.53) | BMP1TAS2R14MMP2MMP9MMP8 | |
| SCHEMBL6324153 | 0.75 | TAS2R14 (0.61) | BMP1TAS2R14MMP2MMP9MMP8 | |
| SCHEMBL6330875 | 0.75 | TAS2R14 (0.58) | BMP1TAS2R14MMP2MMP9MMP8 | |
| SCHEMBL6323929 | 0.75 | TAS2R14 (0.58) | BMP1TAS2R14MMP2MMP9MMP8 | |
| SCHEMBL6323924 | 0.75 | TAS2R14 (0.58) | BMP1TAS2R14MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200069648-A1 | HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-03-05 | — | — | US | disclosed |
| US-20200069648-A1 | HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-03-05 | — | — | US | disclosed |
| CN-110709385-A | Haloallylamine pyrazole derivative inhibitors of lysyl oxidase and uses thereof | 法玛西斯有限公司 | 2020-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069648-A1 | HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | LOX, DAO, AADAC | BMP1 2101/4885TAS2R14 4581/4885MMP2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.